Clinical characteristics of myasthenia gravis patients with coexistence of AChR and titin antibodies
Open Access
- 28 November 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1679404
Abstract
Objective: This study aimed to investigate the clinical characteristics of patients with myasthenia gravis (MG) who are double-seropositive for acetylcholine receptor antibodies (AChR-Ab + ) and titin antibodies (Titin-Ab + ). Methods: A retrospective analysis was conducted on MG patients hospitalized in the Department of Neurology between March 2020 and June 2024. Patients were categorized into two groups based on antibody profiles: those with AChR antibody positivity alone and those with dual positivity for AChR and titin antibodies. Clinical features, MG classification, and treatment outcomes were compared between the two groups. Results: A total of 35 MG patients were included, comprising 18 with single AChR-Ab + and 17 with AChR-Ab + /Titin-Ab + . The dual antibody-positive group showed a significantly higher proportion of patients with MGFA classification above Class II (47.1%) and a higher rate of thyroid dysfunction (50%) compared to the single antibody-positive group ( p = 0.001). The median age of onset in the dual antibody-positive group was older than that in the single antibody-positive group (67.0 years vs. 58.5 years), although this difference was not statistically significant ( p > 0.05). No significant differences were observed between the two groups in terms of gender, initial symptoms, clinical manifestations, thymic hyperplasia, proportion of thymoma, treatment regimens, or therapeutic outcomes (all p > 0.05). Conclusion: This study provides the first systematic characterization of the clinical profile of AChR-Ab + /Titin-Ab + myasthenia gravis patients in Southwest China. Our findings indicate that dual antibody-positive MG patients are more prone to generalized disease involvement and have a higher susceptibility to thyroid dysfunction.Keywords
Funding Information
- Hospital-level Research Project of Qujing First People’s Hospital (2023YJKTB02)
This publication has 39 references indexed in Scilit:
- Miastenia gravis. Actualización diagnóstica y terapéuticaMedicina Clinica, 2023
- Clinical features of LRP4/agrin‐antibody–positive myasthenia gravis: A multicenter studyMuscle & Nerve, 2020
- Maintenance immunosuppression in myasthenia gravis, an updateJournal of the Neurological Sciences, 2020
- Thyroid disorders in patients with myasthenia gravis: A systematic review and meta-analysisAutoimmunity Reviews, 2019
- Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravisJournal of Neurology, 2017
- Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patientsJournal of Neuroimmunology, 2016
- Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4Autoimmunity Reviews, 2013
- The thymus, thymoma and myasthenia gravisSurgery Today, 2012
- Classification of Myasthenia Gravis Based on Autoantibody StatusArchives of Neurology, 2007
- Anti-Titin Antibodies in Myasthenia GravisArchives of Neurology, 2001